Chemically synthesized short interfering RNA (siRNA) has ushered a new era in the application of RNA interference (RNAi) against viral genes. We have paid particular attention to respiratory viruses that wreak heavy morbidity and mortality worldwide. The clinically signifi cant ones include respiratory syncytial virus (RSV), parainfl uenza virus (PIV) (two Paramyxoviruses), and infl uenza virus (an Orthomyxovirus). As the infection by these viruses is clinically restricted to the respiratory tissues, mainly the lungs, the logical route for the application of the siRNA was also the same, i.e., via the nasal route. Following the initial success of single intranasal siRNA against RSV, we now offer two new strategies: (1) second-generation siRNAs, used against the paramyxoviral RNA polymerase large subunit (L), (2) siRNA cocktail with a novel transfection reagent, used against infl uenza virus. Based on these results, we propose the following consensus for designing intranasal antiviral siRNAs: (a) modifi ed 19-27 nt-long double-stranded siRNAs are functional in the lung, (b) excessive 2′-OMe and 2′-F modifi cations in either or both strands of these siRNAs reduce effi cacy, (c) limited modifi cations in the sense strand are benefi cial, although their precise effi cacy may be position-dependent, (d) cocktail of multiple siRNAs can be highly effective against multiple viral strains and subtypes.
Introduction
Short interfering RNAs (siRNAs) trigger posttranscriptional gene silencing in a variety of metazoan cells and tissues [ 1 ] . Successful use of synthetic double-stranded siRNA in 2001 [ 1 , 2 ] targeting cellular and viral genes in cell culture, opened the door to siRNA as prospective antivirals and drugs for gene therapy. The "fi rstgeneration" siRNAs were designed to mimic the products of the Dicer endonuclease cleavage; they were 19 nt-long duplexes with 3′-terminal 2 nt overhangs and contained natural, unmodifi ed ribose and bases. As reported by us [ 3 , 4 ] and several other laboratories [ 5 -7 ] , these siRNAs proved effective both in cell culture and in animals. effective in treating these infections, are both relatively nonspecifi c and toxic [ 14 ] . Regarding the molecular features, RSV and PIV are nonsegmented negative-strand RNA viruses, belonging to different genera of the Paramyxoviridae family [ 6 ] . In contrast, fl u is an Orthomyxovirus and contains segmented negative-strand RNA genome [ 9 , 10 ] . Coronoviruses such as SARS-CoV contain positive-strand RNA genomes [ 11 ] . A commonality among these RNA viruses is that they encode genes for RNA-dependent RNA polymerase (RdRP) to transcribe and replicate their own genomes, because the host animal cells are devoid of such activity. Many of the potent antiviral siRNAs have, therefore, targeted viral genes coding for RdRP subunits or proteins that are related to RdRP function [ 3 , 4 , 6 , 9 -11 ] . These early studies targeted: P (Phosphoprotein), L (Large) ( see Table 1 ), and N (Nucleocapsid) genes of RSV; P and L genes of PIV; PA and NP genes of Flu; and the replicase gene of SARS-CoV. In all cases, siRNAs were designed against essential viral gene(s), optimized in cell culture and then used intranasally in the appropriate animal model. Antiviral activity was shown against RSV and parainfl uenza virus (PIV) using the BALB/c mouse model as well [ 4 ] . In those studies, optimal results were obtained with siRNAs delivered in complex with either 
Two target sequences in the RSV L gene mRNA (Long strain) with the AAN 19 TT motif (the N 19 regions underlined) are shown on top. The thermodynamic difference (∆∆G) of stability of the two termini is shown in parenthesis. Similar but more detailed considerations went into designing siRNAs against fl u M2 and NP genes (not shown). All subsequent siRNAs were based on sequence #1 as shown. Bold = 2′-O-Me modifi cations; underlined = 2′-F modifi cations. We have confi rmed the antiviral effi cacy of both of these modifi ed sequences in cell culture as well as in mice (data not shown). The dTdT part adds stability to the siRNA Oligofectamine (Invitrogen, Carlsbad, CA) or Mirus Transit TKO reagent ( see Subheading 2 ), although uncomplexed intranasal siRNA also showed some effi cacy [ 4 ] . Intranasal siRNA, complexed with oligofectamine or polyethyleneimine (PEI), was also protective against highly pathogenic infl uenza A viruses of the H5 and H7 subtypes in mice [ 9 , 10 ] . Notwithstanding their success, the activity of these siRNAs was transient, lasting only a few days. Therefore, enhancement of the intracellular and extracellular stability of synthetic siRNAs while increasing (or without compromising) their RNAi activity is a continuing goal for therapeutic translation of RNAi. A variety of chemical modifi cations, including terminal and internal ones, have been added to the fi rst-generation siRNA sequences to improve stability and delivery, leading to what we call "second-generation" siRNAs. Advantage has been taken of the free 2′-OH group of the ribose moiety of RNA (in contrast to DNA that lacks this OH group), to which various substituents were added. We have pursued two promising ones, namely 2′-O-methyl (2′-O-Me) and 2′-fl uoride (2′-F). The latter modification is placed on pyrimidine nucleosides (C, U), leading to 2′-FC and 2′-FU residues. In a number of previous studies [ 16 -19 ] , these substitutions were introduced to various extents in the antisense strand ("guide" strand) or both strands of the siRNA and were shown to enhance stability and potency, although intranasal application was not tested. Additionally, they tend to reduce siRNA-driven innate immune response [ 20 , 21 ] . In systematic studies in cell culture, the biochemical and functional activity of the siRNA was vindicated but found to be affected by the position of the modifi cations in the sequence [ 16 -19 ] . Generally speaking, those with the modifi ed ribonucleotides at the 5′-end of the antisense strand were less active relative to the 3′-modifi ed ones. Internally, while 2′-F was generally well-tolerated on the antisense strand, 2′-O-Me showed signifi cant shift in activity depending on the position. In contrast, incorporation of 2′-O-Me in the sense strand of siRNA did not show a strong positional preference. In a comprehensive study, however, internal 2′-O-Me modifi cations in either or both strands actually made the siRNA less active [ 22 ] . In an animal experiment [ 23 ] , all the 2′-OH residues in siRNAs against hepatitis B virus were substituted with 2′-F and 2′-O-Me. When administered intravenously (i.v.) as lipid complexes, the 2′-O-Me, 2′-F siRNAs showed improved effi cacy and longer halflife in plasma and liver. When these siRNAs were additionally Cy3labeled, it revealed their accumulation in the liver and spleen, but not in the lung, explaining the success of the i.v. administration against hepatitis while suggesting that it is an ineffective route against lung infections.
Based on the absence of a uniform pattern in these studies, we reasoned that siRNAs against respiratory viruses should be individually optimized through the following steps: (1) Design the fi rst-generation siRNA following the generally accepted sequence rules or an algorithm of your choice. (2) Select the ones with lowest IC 50 (preferably below ~20 nM) in a cell culture assay for virus growth, (3) If desired, as we did for RSV (Table 1 ) , add OMe and F substitutions in various "format" (i.e., number and placement) to generate modifi ed, "second-generation" siRNAs. (4) Ensure that the substitutions either improved or did not reduce knockdown effi ciency by screening in cell culture, (5) Confi rm effi cacy and lack of toxicity in animal model, and (6) test improved stability in serum and blood in vitro. Finally, if deemed necessary and resources permit, a low-or high-throughput assay for off-target effects can be performed to further ensure target specifi city.
Together, the small but representative datasets cover multiple viruses, modifi ed and unmodifi ed siRNA. We present a consensus procedure tested in our laboratory, but essentially the same protocol can be used to test other modifi cations or delivery reagents as they become available. In fl u, for example, we have found that the HK polymer is in fact better than a number of other reagents tested ( Fig. 1 ).
Materials
The reagents described below have been used successfully by us but various equivalents are available commercially that can be optimized. We assume that the reader has access to an appropriate cell culture facility, consisting of incubators and culture hoods, and there is available expertise on virus growth and assay. In this chapter, we will only cover specifi c issues related to the testing of antiviral siRNA against RSV. 3. RNase-free gel-loading microcapillary tips (VWR).
4.
RNase-free microfuge tubes (Ambion).
siRNAs and Their Use
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Methods
1. Use a free online siRNA design program for your target mRNA sequence ( see Note 1 ). We generally use the one available on the Whitehead Institute (MIT) server at the following URL ( http://sirna.wi.mit.edu/ ); registration is required but free. Copy and paste the target sequence in the box and initially choose AAN 19 TT in the "recommended patterns." Usually, there is no need to change the "Filter criteria" below, i.e., leave them as in the default. Click on the Search button. With RSV L gene, we found many prospective ones ( Table 1 ) , but if no siRNA is obtained with your gene sequence, repeat the procedure, this time choosing NAN 21 .
With fl u, a proprietary algorithm was used and thus, the siRNA sequences ( Fig. 2 ) are also intellectual property. In general, for a wider coverage of multiple virus strains and to minimize resistance, choose viral sequences that are most conserved.
2. This will lead to a table of prospective siRNA sequences that are ordered according to "Thermodynamic values" by the default setting. The goal is to select sequences with high negative values, i.e., sequences closer to the top of the table. In addition, visually examine the central N 19 part (i.e., ignore the fi rst two and the last two nucleotides) and pick the ones that are AT-rich at the 3′-end (right hand side) and GC-rich at the Fig. 2 High effi ciency of the HK polymer in siRNA transfection. A propreitary siRNA against human cyclophilin B mRNA was tested for delivery into HEp-2 cells using the following reagents: His-Lys polymer (HKP) with selected branching [ 27 , 28 ] ; the cationic lipid, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) [ 29 ] ; and 5 % glucose (dextrose) in water (D5W), a common physiological solution used in the clinic. Blank is siRNA administered with no transfection reagent. Note the strong performance of HKP, especially discernible with 10 μg siRNA 5′-end (left hand side). The number of sequences one can test really depends on available resources, but order at least 3 for a given target. Order the sense strand as N 19 dTdT and the antisense strand as (N′) 19 dTdT, such that the N′ part is complementary to the N 19 sequence. Here, we provide an example of tested functional siRNA sequences based on the L polymerase gene of RSV ( Table 1 ). Assume that you will receive the siRNA roughly a week after ordering. Purchase the smallest amount initially (to save money), generally 2 nmol of each.
siRNA Sequence Design
3. After receiving the lyophilized RNA (2 nmol), briefl y spin the tubes to ensure that the RNA is at the bottom. Add 42 μl 1× siRNA buffer to each RNA. Pipette the solution up and down 8-10 times, avoiding the introduction of bubbles.
4. Place the solution on an orbital mixer/shaker for 30 min at room temperature for complete mixing. Briefl y centrifuge the tubes containing siRNA to ensure that the solution is collected at the bottom of the tube.
5.
Combine the volumes of the complementary strands of RNA (42 + 42 = 84 μl), vortex for 10 s and centrifuge for 30 s. Add 16 μl of 6× siRNA buffer to make 100 μl, mix.
6. Heat the mixture at 60 °C for 45 min.
7. Remove from heat and centrifuge briefl y, 5-10 s.
8. Allow solution to cool to room temperature over 30 min to allow formation of the double-stranded siRNA, which is now ready to use. The siRNA concentration of this stock solution is 20 μM ( see Notes 2 and 3 ).
9. Aliquot the siRNA into small volumes and store at −20 to −80 °C. For best results, do not freeze-thaw more than four times.
1. Trypsinize cells and seed ~5 × 10 4 cells in 500 μl complete growth medium per well of a 24-well plate. Incubate for 24 h to achieve a confl uency of 60-70 %.
2. Immediately before transfection, add 50 μl of Opti-MEM I to a sterile Eppendorf tube. To this, add 2.5 μl TransIT-TKO reagent, mix thoroughly by vortexing, and incubate at room temperature for 10-20 min.
3. Dilute the siRNA 20-fold by mixing 3.5 μl of the stock with 66.5 μl siRNA buffer. Test three concentrations of each siRNA, and each concentration at least in duplicate, and if possible, triplicate. The fi nal concentrations and the corresponding volumes are: 5 nM (1.5 μl), 10 nM (3 μl), and 50 nM (15 μl). Add these volumes to the diluted transfection reagent made in step 2 above and mix by gentle pipetting. Incubate at room temperature for 10-20 min.
Reiterated Testing of Modifi ed and Unmodifi ed siRNA
4. Adjust the medium volume in each well of the 24-well cell monolayer ( step 1 above) to 250 μl by removing half of the original volume (250 μl).
5.
Add the transfection-ready siRNA mixture (from step 3 ) dropwise to the cells. Gently tilt and rock the plate to evenly distribute the complexes. (a) Introduce 2′-O-Me modifi cations in all sites in the sense strand initially, but then try less extensive modifi cations (at various positions), which are sometimes more effective.
(b) Introduce alternate modifi cations in sense and antisense strands. Start with 2′-F (in available C's and U's) followed by 2′-O-Me in the sense strand, and reciprocate in the antisense strand (Table 1 ) . Order the modifi ed siRNA from commercial sources (e.g., Dharmacon) and then process them as in steps 3 -9 (Subheading 3.2 ).
Prior to the intranasal administration of siRNA, the mouse ( see Note 2 ) must be anesthetized by using any standard procedure available in the laboratory, e.g., by administering Nembutal via
siRNA Testing in Mice
intraperitoneal (IP) injection. The recommended drug dosage for mice is 50 mg/kg ( see Note 3 ).
1. Gently lift the mouse by the tail and place it on a cage lid.
2. Grip the loose skin of the neck to immobilize the head of the mouse. Extend the tail to draw the skin tight over the abdomen by gripping the tail with your little fi nger.
3. Hold mouse in a head-down position and disinfect injection site (the lower right or left quadrant of the abdomen); use a hypodermic needle to administer the anesthetic. The mouse is ready for siRNA administration when no voluntary movement is observed.
4. Place the anesthetized mouse on a lab towel facing up; with its head immobilized, insert microcapillary tip containing siRNA/ transfection reagent complexes ( see Note 4 ) into the nostril. Use a range of 2-20 nmol siRNA per mouse (e.g., 2, 6, 10 nmol). Instill solution slowly over a 2-3 min period, allowing the animal to breathe the liquid in ( see Note 5 ).
5.
Return the mouse to the cage and monitor for at least 45 min to avoid depression of cardiac and/or respiratory functions.
6. Test for the desired RNAi effect at appropriate intervals. For antiviral studies, instill virus through the nostril as well. For human RSV, which does not infect mice well, use 10 7 -10 8 virus particles per animal, and measure standard lung titer assay and/or clinical symptoms (such as body weight, respiration rate, etc.) ( see Note 6 ).
Notes
(e.g., mg/kg). For the researcher, however, it is easier and more useful to express siRNA concentrations in molar units (e.g., μM or nM), since this allows direct comparison between the potency of different siRNAs even when they differ in base composition or modifi cations (and hence formula weight).
4. Transfection reagent: siRNAs may respond differently to different reagents. Experiment with delivery reagent of your choice (Fig. 2 ) .
5. Avoid using excessive liquid because it may suffocate the animal and cause death. As a rule, keep the total instilled volume under 45 μl for BALB/c mice, but higher volumes may be tolerated by larger species. 6. The protocol described here may be modifi ed for aerosolized siRNA using an enclosure to house the anesthetized animal and a handheld nebulizer (the common type used as an inhaler by asthmatics). A larger amount of siRNA is needed because only a fraction of the aerosol is actually inhaled by the animal. If used routinely, consider optimizing a commercial motorized nebulizer. Check with the local pediatricians for the exact model, vendor, and usage. Modify the system by removing the facial mask at the delivery end and inserting the tube directly into the enclosure. A snug fi t of the mask should reduce siRNA waste.
